TTY Biopharm Company Limited (4105.TWO)
- Previous Close
75.80 - Open
76.00 - Bid 75.50 x --
- Ask 75.90 x --
- Day's Range
75.30 - 76.00 - 52 Week Range
66.20 - 80.90 - Volume
216,757 - Avg. Volume
956,446 - Market Cap (intraday)
18.873B - Beta (5Y Monthly) --
- PE Ratio (TTM)
12.12 - EPS (TTM)
6.26 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield 4.20 (5.54%)
- Ex-Dividend Date Mar 27, 2025
- 1y Target Est
78.00
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
www.tty.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4105.TWO
View MorePerformance Overview: 4105.TWO
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4105.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4105.TWO
View MoreValuation Measures
Market Cap
18.85B
Enterprise Value
17.16B
Trailing P/E
12.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.11
Price/Book (mrq)
3.08
Enterprise Value/Revenue
2.82
Enterprise Value/EBITDA
7.56
Financial Highlights
Profitability and Income Statement
Profit Margin
25.66%
Return on Assets (ttm)
8.88%
Return on Equity (ttm)
25.10%
Revenue (ttm)
6.08B
Net Income Avi to Common (ttm)
1.56B
Diluted EPS (ttm)
6.26
Balance Sheet and Cash Flow
Total Cash (mrq)
2.9B
Total Debt/Equity (mrq)
16.14%
Levered Free Cash Flow (ttm)
1.1B